BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34344865)

  • 21. Silencing of ZFP36L2 increases sensitivity to temozolomide through G2/M cell cycle arrest and BAX mediated apoptosis in GBM cells.
    Che Mat MF; Mohamad Hanif EA; Abdul Murad NA; Ibrahim K; Harun R; Jamal R
    Mol Biol Rep; 2021 Feb; 48(2):1493-1503. PubMed ID: 33590411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
    Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW
    Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A direct comparison of selective BH3-mimetics reveals BCL-X
    Bierbrauer A; Jacob M; Vogler M; Fulda S
    Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
    Murphy ÁC; Weyhenmeyer B; Noonan J; Kilbride SM; Schimansky S; Loh KP; Kögel D; Letai AG; Prehn JH; Murphy BM
    Apoptosis; 2014 Apr; 19(4):629-42. PubMed ID: 24213561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.
    Day BW; Stringer BW; Spanevello MD; Charmsaz S; Jamieson PR; Ensbey KS; Carter JC; Cox JM; Ellis VJ; Brown CL; Walker DG; Inglis PL; Allan S; Reynolds BA; Lickliter JD; Boyd AW
    Neuro Oncol; 2011 Nov; 13(11):1202-12. PubMed ID: 21846680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
    Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
    Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD.
    Pareja F; Macleod D; Shu C; Crary JF; Canoll PD; Ross AH; Siegelin MD
    Mol Cancer Res; 2014 Jul; 12(7):987-1001. PubMed ID: 24757258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eupafolin enhances TRAIL-mediated apoptosis through cathepsin S-induced down-regulation of Mcl-1 expression and AMPK-mediated Bim up-regulation in renal carcinoma Caki cells.
    Han MA; Min KJ; Woo SM; Seo BR; Kwon TK
    Oncotarget; 2016 Oct; 7(40):65707-65720. PubMed ID: 27582546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
    Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
    Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
    Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
    Eguchi T; Itadani H; Shimomura T; Kawanishi N; Hirai H; Kotani H
    Mol Cancer Ther; 2009 Jun; 8(6):1460-72. PubMed ID: 19509251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY
    Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329
    [No Abstract]   [Full Text] [Related]  

  • 37. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis.
    Leitch AE; Riley NA; Sheldrake TA; Festa M; Fox S; Duffin R; Haslett C; Rossi AG
    Eur J Immunol; 2010 Apr; 40(4):1127-38. PubMed ID: 20127676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of Mcl-1 is required for protection against serum starvation in phosphatase and tensin homologue on chromosome 10 null mouse embryonic fibroblasts, but repression of Bim is favored in human glioblastomas.
    Austin M; Cook SJ
    J Biol Chem; 2005 Sep; 280(39):33280-8. PubMed ID: 16051596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.